Show simple item record

dc.contributor.authorRos, S
dc.contributor.authorWright, AJ
dc.contributor.authorBruna, A
dc.contributor.authorCaldas, C
dc.contributor.authorBrindle, KM
dc.date.accessioned2021-07-13T15:19:11Z
dc.date.available2021-07-13T15:19:11Z
dc.identifier.citationSTAR protocols, 2021, 2 (3), pp. 100608 - ?en_US
dc.identifier.issn2666-1667
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4685
dc.identifier.eissn2666-1667en_US
dc.identifier.eissn2666-1667
dc.identifier.doi10.1016/j.xpro.2021.100608en_US
dc.identifier.doi10.1016/j.xpro.2021.100608
dc.description.abstract<sup>13</sup>C nuclear spin hyperpolarization can increase the sensitivity of detection in an MRI experiment by more than 10,000-fold. <sup>13</sup>C magnetic resonance spectroscopic imaging (MRSI) of hyperpolarized <sup>13</sup>C label exchange between injected [1-<sup>13</sup>C]pyruvate and the endogenous tumor lactate pool can be used clinically to assess tumor grade and response to treatment. We describe here an experimental protocol for using this technique in patient-derived and established cell line xenograft models of breast cancer in the mouse. For complete details on the use and execution of this protocol, please refer to Ros et al. (2020).en_US
dc.formatElectronic-eCollectionen_US
dc.format.extent100608 - ?en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.titleMetabolic imaging with hyperpolarized [1-<sup>13</sup>C] pyruvate in patient-derived preclinical mouse models of breast cancer.en_US
dc.typeJournal Article
dcterms.dateAccepted2021-09-17
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.1016/j.xpro.2021.100608en_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0en_US
dc.relation.isPartOfSTAR protocolsen_US
pubs.issue3en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Preclinical Modelling of Paediatric Cancer Evolution
pubs.publication-statusAccepteden_US
pubs.volume2en_US
pubs.embargo.termsNot knownen_US
icr.researchteamPreclinical Modelling of Paediatric Cancer Evolution
dc.contributor.icrauthorBruna Cabot, Alejandraen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/